Business Wire

ADVA

9.7.2020 09:02:08 CEST | Business Wire | Press release

Share
KCOM extends high-speed connectivity with ADVA’s packet edge solution

ADVA (FSE: ADV) today announced that KCOM has deployed its packet edge technology to support the extended rollout of super-fast full fiber broadband. Using the compact ADVA FSP 150 demarcation and aggregation device, the UK-based communication and IT service provider is delivering its gigabit-speed Lightstream services to tens of thousands more business and residential customers in the Yorkshire and Lincolnshire area. The high-density MEF 3.0-certified technology enables KCOM to smoothly transition from 1Gbit/s to 10Gbit/s services in its access network. ADVA’s packet edge solution also ensures that the new infrastructure is ready for 5G mobile services and can easily scale to 200Gbit/s.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005034/en/

“Our Lightstream service has already had a huge impact on businesses and in homes across this region. Now, ADVA’s technology is empowering us to go further than ever before by creating the UK’s first full-fiber city and delivering super-fast fiber connectivity to previously underserved areas,” said Tim Shaw, managing director, wholesale and networks, KCOM. “By leveraging ADVA’s packet edge device, we’ve been able to smoothly transition to 100Gbit/s capacity in our access network and aggregate lower-speed services. What makes the solution so valuable though are its extra benefits. As well as a small footprint and low power, ADVA’s packet edge technology comes with fully automated service activation. Together with its extended temperature range, this makes it simple to deploy in any environment and on a large scale.”

KCOM’s new network is built on ADVA's 100Gbit/s FSP 150 solution with MEF 3.0 Carrier Ethernet certification. The technology supports 100Gbit/s demarcation and high-scale 10Gbit/s service aggregation in an incredibly compact form factor. KCOM is managing the infrastructure with ADVA’s Ensemble Controller , a unique management system that enables programmatic SDN control. This further improves efficiency by reducing troublesome and time-consuming manual processes while providing KCOM’s maintenance team with total visibility. With its hardware-based timing and full activation testing, the solution also helps KCOM ensure the highest levels of quality and availability. What’s more, its low power consumption and ultra-compact design are key to keeping the cost of KCOM’s Lightstream services low.

“We’re proud to be supporting KCOM in this next phase of its journey. By harnessing our technology and the expertise of our team, KCOM is providing high-speed connectivity to more properties than ever before. It’s also helping to boost the economy in this region of the UK by empowering businesses to expand and seize new revenue opportunities,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our FSP 150 packet edge device features several unique advantages, such as its unique ability to verify the performance of high-bitrate services with line-rate 100Gbit/s pre-activation testing. It really is the ultimate tool for operators who need to scale their networks quickly and affordably to tackle exponential growth in data demand and lay the foundations for 5G.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About KCOM

KCOM is a leading provider of communications and IT services. Its foundations date back to 1904 when Hull’s local authority established its own telephone network and it is the reason Hull is the only city in the UK where BT does not operate. KCOM was owned entirely by Hull City Council until its flotation on the London Stock Exchange in 1999 and in August 2019 it was acquired for £627m by Macquarie European Infrastructure Fund 6, an investment fund managed by Macquarie Infrastructure and Real Assets (MIRA). The company has a long history of innovation. It installed the first all-digital telephone network in Europe and launched the first commercial broadband service in the UK. It also introduced the UK’s first online TV service in 1999, pre-empting today’s streaming and downloading technology by decades. Today KCOM provides broadband and phone services to more than 140,000 consumers and businesses in Hull and East Yorkshire while its national arm provides connectivity and IT services to public and private sector organisations across the UK. www.kcom.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye